250 related articles for article (PubMed ID: 36612293)
21. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Privé BM; Slootbeek PHJ; Laarhuis BI; Naga SP; van der Doelen MJ; van Kalmthout LWM; de Keizer B; Ezziddin S; Kratochwil C; Morgenstern A; Bruchertseifer F; Ligtenberg MJL; Witjes JA; van Oort IM; Gotthardt M; Heskamp S; Janssen MJR; Gerritsen WR; Nagarajah J; Mehra N
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):71-78. PubMed ID: 34253846
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study).
Chua WM; Lam WW; Tong AK; Sultana R; Kua SMY; Kanesvaran R; Wong ASC; Tay KJ; Cheng TJL; Ng DCE; Thang SP
Asia Pac J Clin Oncol; 2023 Mar; ():. PubMed ID: 36999335
[TBL] [Abstract][Full Text] [Related]
23. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
24. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
[TBL] [Abstract][Full Text] [Related]
25. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
[TBL] [Abstract][Full Text] [Related]
26. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
27. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
28. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
29. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
30. Salvage Radioligand Therapy with Repeated Cycles of
Groener D; Baumgarten J; Haefele S; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Tselis N; Chun FKH; Grünwald F; Sabet A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439172
[TBL] [Abstract][Full Text] [Related]
31. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2
Prasad V; Huang K; Prasad S; Makowski MR; Czech N; Brenner W
Front Oncol; 2021; 11():578093. PubMed ID: 33816225
[TBL] [Abstract][Full Text] [Related]
32. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [
Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38635050
[TBL] [Abstract][Full Text] [Related]
33. Matched-pair analysis of [
Hartrampf PE; Weinzierl FX; Buck AK; Rowe SP; Higuchi T; Seitz AK; Kübler H; Schirbel A; Essler M; Bundschuh RA; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3269-3276. PubMed ID: 35243517
[TBL] [Abstract][Full Text] [Related]
34. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
Satapathy S; Das CK; Aggarwal P; Sood A; Parihar AS; Singh SK; Mittal BR
Prostate; 2023 Feb; 83(2):169-178. PubMed ID: 36259290
[TBL] [Abstract][Full Text] [Related]
35. Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Zisser L; Yu J; Oszwald A; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat SF; Mitterhauser M; Vraka C; Hacker M; Haug AR; Rasul S
Nucl Med Commun; 2022 Nov; 43(11):1113-1120. PubMed ID: 36120814
[TBL] [Abstract][Full Text] [Related]
36. Outcome of
Mader N; Groener D; Tselis N; Banek S; Nagarajah J; Grünwald F; Sabet A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439347
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.
Parida GK; Panda RA; Bishnoi K; Agrawal K
Med Princ Pract; 2023; 32(3):178-191. PubMed ID: 37247612
[TBL] [Abstract][Full Text] [Related]
38. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
39. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
Wrenger R; Jüptner M; Marx M; Zhao Y; Zuhayra M; Caliebe A; Osmonov D; Lützen U
BMC Urol; 2022 Jul; 22(1):96. PubMed ID: 35788220
[TBL] [Abstract][Full Text] [Related]
40. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [
Hartrampf PE; Seitz AK; Weinzierl FX; Serfling SE; Schirbel A; Rowe SP; Kübler H; Buck AK; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4262-4270. PubMed ID: 35650263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]